Journal of Obesity & Weight Loss Therapy
Open Access

Obesity has become a global epidemic, significantly increasing the risk of chronic diseases such as type 2 diabetes, cardiovascular disorders, and metabolic syndrome. The management of obesity requires a multifaceted approach, including lifestyle modifications, pharmacological interventions, and, in severe cases, surgical procedures. While diet and exercise remain fundamental in weight management, they are often insufficient for individuals with severe obesity or metabolic complications [1].

Anti-obesity medications and bariatric surgery are two major interventions for long-term weight loss and metabolic rate regulation. Anti-obesity medications work through various mechanisms, such as appetite suppression, fat absorption reduction, and metabolic enhancement. In contrast, bariatric surgery involves anatomical modifications of the digestive system to promote significant and sustained weight loss. Both approaches have their advantages and limitations, making it essential to compare their efficacy, safety, sustainability, and impact on metabolic rate regulation. This article provides a detailed comparative analysis of anti-obesity medications and bariatric surgery, exploring their mechanisms, outcomes, risks, and long-term effectiveness [2].

Description

Anti-obesity medications: Mechanisms and effectiveness

Anti-obesity medications, also known as pharmacotherapy for obesity, are designed to assist in weight loss by targeting specific physiological processes that regulate appetite, metabolism, and fat absorption.

Major classes of anti-obesity medications

Appetite suppressants (Anorectics)

Medications such as phentermine and lorcaserin act on the central nervous system to reduce hunger and increase satiety.

These drugs primarily affect neurotransmitters like norepinephrine, serotonin, and dopamine, which play a role in appetite control.

Gastrointestinal fat absorption inhibitors

Orlistat is a lipase inhibitor that reduces fat absorption in the intestines by inhibiting pancreatic lipase enzymes.

This leads to reduced calorie intake, promoting weight loss.

Glucagon-like peptide-1 (GLP-1) receptor agonists

Liraglutide (saxenda) and semaglutide (wegovy) mimic the GLP-1 hormone, which enhances insulin secretion, slows gastric emptying, and reduces appetite.

These medications have shown significant weight loss benefits and improvements in metabolic parameters.

Combination therapies

Phentermine-topiramate (Qsymia) and Bupropion-Naltrexone (contrave) combine different mechanisms to improve weight loss efficacy.

They work by suppressing appetite, increasing satiety, and enhancing energy expenditure.

Effectiveness of anti-obesity medications

Clinical trials show that patients lose an average of 5% to 15% of their body weight within 6 to 12 months of treatment, depending on the medication used.

Medications like semaglutide have demonstrated weight loss of up to 20% of body weight, making them one of the most effective pharmacological options [3].

However, long-term weight maintenance is challenging, as discontinuing these medications often leads to weight regain.

Risks and limitations

Side effects: Common issues include nausea, diarrhea, insomnia, increased heart rate, and gastrointestinal discomfort.

Limited efficacy for severe obesity: Medications alone may not be sufficient for individuals with a Body Mass Index (BMI) greater than 40 or those with severe metabolic disorders.

Potential for dependency: Some appetite suppressants have the potential for abuse or dependency, requiring careful prescription monitoring.

Bariatric surgery: Types and long-term outcomes

Bariatric surgery is a surgical intervention designed for individuals with severe obesity (BMI ≥40 or BMI ≥35 with comorbidities). It significantly alters the digestive system to promote weight loss and metabolic improvements [4].

Major types of bariatric surgery

Roux-en-Y gastric bypass (RYGB)

A small stomach pouch is created and connected directly to the small intestine, bypassing a significant portion of the stomach and duodenum [5].

This leads to reduced calorie absorption and significant hormonal changes that promote weight loss and metabolic regulation.

Sleeve gastrectomy (SG)

About 75-80% of the stomach is removed, reducing its capacity and altering hunger-regulating hormones such as ghrelin.

It is one of the most commonly performed procedures due to its effectiveness and lower complication rates.

Adjustable gastric banding (AGB)

A silicone band is placed around the upper part of the stomach to limit food intake.

This method is less invasive but has lower long-term success rates compared to bypass and sleeve procedures.

Biliopancreatic diversion with duodenal switch (BPD/DS)

A more complex procedure that involves removing a large part of the stomach and rerouting food away from most of the small intestine.

It results in the highest weight loss but has greater nutritional deficiencies and complications.

Effectiveness of bariatric surgery

Studies show that bariatric surgery results in an average weight loss of 25% to 35% of total body weight within the first year.

Weight loss is often sustained for over 10 years, with gastric bypass and sleeve gastrectomy showing the best long-term outcomes [6].

Improves metabolic rate regulation: Enhances insulin sensitivity, reduces inflammation, and lowers the risk of diabetes and cardiovascular diseases.

Risks and limitations

Surgical risks: Complications include infections, bleeding, blood clots, and leaks from surgical sites.

Nutritional deficiencies: Malabsorption of vitamins (B12, D) and minerals (iron, calcium) requires lifelong supplementation [7].

Psychological Impact: Patients may experience body image concerns, depression, or difficulty adjusting to lifestyle changes.

Permanent Alteration: Unlike medications, surgery involves irreversible anatomical changes [8].

Conclusion

Both anti-obesity medications and bariatric surgery play crucial roles in weight loss and metabolic regulation, but they serve different patient populations and offer varying degrees of effectiveness. Anti-obesity medications provide a non-invasive, reversible option for moderate weight loss and metabolic control. However, their effectiveness is often limited, requiring continuous use to maintain results. Bariatric surgery remains the most effective long-term solution, particularly for individuals with severe obesity and metabolic complications. It not only promotes significant weight loss but also improves metabolic health, often leading to diabetes remission and cardiovascular risk reduction. Ultimately, the choice between pharmacological and surgical interventions depends on patient eligibility, medical history, weight loss goals, and risk tolerance. A personalized approach that integrates lifestyle changes, behavioral therapy, and medical or surgical interventions ensures the best long-term success in obesity management.

Acknowledgement

None

Conflict of Interest

None

References

1. Fock KM, Ang TL (2010) Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 25: 479-486.

   Indexed at, Google Scholar, CrossRef

2. Thrift AP (2020) Global burden and epidemiology of Barrett esophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol 18: 432-443.

   Indexed at, Google Scholar, CrossRef

3. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33: 547-594.

   Indexed at, Google Scholar, CrossRef

4. Wiklund P, Toss F, Weinehall L, Göran Hallmans, Franks PW, et al. (2008) Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women. J Clin Endocrinol Metab 93: 4360-4366.

   Indexed at, Google Scholar, CrossRef

5. Chooi YC, Ding C, Magkos F (2019) The epidemiology of obesity. Metabolism 92: 6-10.

   Indexed at, Google Scholar, CrossRef

6. Anuurad E, Shiwaku K, Nogi A, Kitajima K, Enkhmaa B, et al. (2003) The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health 45: 335-343.

   Indexed at, Google Scholar, CrossRef

7. Wiklund P, Toss F, Weinehall L, Hallmans G, Franks PW, et al. (2008) Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women. J Clin Endocrinol Metab 93: 4360-4366.

   Indexed at, Google Scholar, CrossRef

8. Piché ME, Poirier P, Lemieux I, Després JP (2018) Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. Prog Cardiovasc Dis 61: 103-113.

   Indexed at, Google Scholar, CrossRef